Basit öğe kaydını göster

dc.contributor.authorDursun, Adile Berna
dc.contributor.authorŞahin, Osman Zikrullah
dc.date.accessioned2020-12-19T20:02:57Z
dc.date.available2020-12-19T20:02:57Z
dc.date.issued2014
dc.identifier.citationDursun, A.B., Sahin, O.Z., (2014).Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report.Allergy Asthma and Clinical Immunology, 10, 52. https://doi.org/10.1186/1710-1492-10-52
dc.identifier.issn1710-1492
dc.identifier.urihttps://doi.org/10.1186/1710-1492-10-52
dc.identifier.urihttps://hdl.handle.net/11436/3040
dc.descriptionDursun, A. Berna/0000-0002-6337-6326en_US
dc.descriptionWOS: 000346025100001en_US
dc.descriptionPubMed: 25685161en_US
dc.description.abstractBackground: Allopurinol is an effective urate-lowering drug that is well tolerated by the majority of patients. Patients with chronic renal insufficiency have an increased risk of hypersensitivity reactions with allopurinol. Case presentation: 75 year old male patient with gout, renal insufficiency, history of metastatic colorectal carcinoma status post-resection was referred to Allergy clinic for a maculopapular eruption that developed 1 week after initiating therapy with allopurinol. the rash resolved with discontinuation of allopurinol. However, his serum urate level rose to 19.9 mg/dl. We initially proposed a slow 4 week oral allopurinol desensitization. the treating nephrologist felt it was critical to lower urate more rapidly. As a result, we modified the dose and standard 4 week protocol down to 2 weeks. A suspension of allopurinol was prepared by the allergy nurse practitioner with a 300 mg allopurinol tablet. the sensitization protocol was modified as a starting dose of 0.3 mg escalating to a final dose of 300 mg/day in 2 weeks. There was no reaction during or after the desensitization. the patient's urate level normalized (6.3 mg/dl) and has continued on 300 mg allopurinol daily without reaction. Conclusion: A 2 week modified allopurinol desensitization protocol is a safe alternative for elderly patients with multiple comorbidities.en_US
dc.language.isoengen_US
dc.publisherBmcen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAllopurinol hypersensitivtyen_US
dc.subjectOral drug desensitizationen_US
dc.subjectSlow desensitizationen_US
dc.subjectHyperuricemiaen_US
dc.subjectGouten_US
dc.subjectMaculopapular exanthemaen_US
dc.titleAllopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case reporten_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorDursun, Adile Berna
dc.contributor.institutionauthorŞahin, Osman Zikrullah
dc.identifier.doi10.1186/1710-1492-10-52
dc.identifier.volume10en_US
dc.ri.editoaen_US
dc.relation.journalAllergy Asthma and Clinical Immunologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster